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Abstract
Background: The intermediate filament forming protein keratin 8 (K8) is a tumour-associated
antigen, which was shown to be over-expressed in a variety of malignancies. Here, we present a
study of K8 expression in squamous epithelia of the head and neck area, including normal mucosa,
hyperplastic and dysplastic leukoplakia, carcinomas of different sub-localisations, and lymph node
metastases.
Methods: K8 expression was assessed upon immunohistochemistry with specific antibodies in
cryosections of primary tumours of the head and neck area.
Results: K8 expression was characteristic of transformed tissue and marked early stages of
disease,  i.e.  dysplastic oral leukoplakia, but not normal or hyperplastic epithelium. With the
exception of carcinomas of the larynx and the tongue, K8 expression also strictly differentiated
carcinomas from normal epithelium of the same origin. Furthermore, K8high was characteristic of
cells, which had detached from the sites of primary tumours and had been invading the surrounding
tissue at the time point of surgery.
Conclusion: K8 is an excellent marker for head and neck malignancies, which allows for early
detection as well as for visualisation of potentially disseminating tumour cells in vivo.
Background
Cytokeratin 8 (K8) is a structural protein, which forms
intermediate filaments within the cytoplasm of simple
epithelial cells [1] as a dimer with CK18 [2]. Along with
other keratins, K8/CK18 generate a stabilizing framework,
which is cell shape determining and allows cells to cope
with mechanical stress. Cytokeratin filaments further on
represent a mesh of "paths" on which signalling mole-
cules, metabolites, and pathogens can travel the cell in an
orientated fashion. The regulation of the localization of
K8 within cells and polymerization into intermediate fila-
ments is dependent upon its phosphorylation. Two main
kinase families are instrumental in this context: the MAP
kinase family member p38 [3] and PKC-ε related kinase
[4]. Phosphorylation of K8 at serine in position 73 (Ser73)
is mediated by p38 under stress such as orthovanadate
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treatment, and regulates keratin organization [5]. High
p38 kinase activity correlated with the formation of kera-
tin granules, while low p38 activity, ergo  low K8 Ser73
phosphorylation, was associated with a prevented disas-
sembly of the filament network [5]. As a potential coun-
ter-regulator and eventually in order to balance the
phosphorylation status of K8, the catalytic subunit of pro-
tein phosphatase 2A (PP2A) associates with and dephos-
phorylates K8 after hyposmotic stress [6]. However,
dephosphorylation was site-specific and concerned Ser431,
not Ser73. Additionally, K8 and CK18 hyperphosphoryla-
tion is a valuable marker for the progression of liver dis-
eases such as non-cirrhotic hepatitis C infection or
cirrhosis [7]. Disease associated mutations of K8 were
reported for the case of cryptogenic liver diseases with sin-
gle point mutations leading to the exchange of glycine at
position 61 to a cysteine residue and of tyrosine53 to a his-
tidine [8,9]. Gly61 → Cys mutation was of major impor-
tance as it diminished the capacity of cells to reorganize
keratin filament. Recently, Ku and colleagues reported on
an animal model for the Gly61 → Cys mutation. In trans-
genic mice, this point mutant of K8 predisposed animals
to liver injury along with a decreased Ser73 phosphoryla-
tion [10]. When ectopically expressed at the plasma mem-
brane of carcinoma cells [11], K8 serves as a tissue-type
plasminogen activator (tPA) [12-15] and might help
tumour cells to remodel or invade surrounding tissue
[16].
Generally speaking, K8 is believed to be involved in the
process of carcinogenesis [17-21] and silencing of it
resulted in sensitization for cisplatin [22]. We have iso-
lated K8 as a tumour-associated antigen, which elicits a
humoral response in vivo in patients suffering from carci-
nomas of the head and neck area [23]. A continuative
study on the profile of K8-specific autoantibodies in
healthy donors and patients revealed that autoantibody
titers allowed to differentiate normal and diseased per-
sons, but not to discriminate between cases of benign and
malignant disease [24]. Normal squamous epithelium,
which represents the great majority of epithelia of the
head and neck and of malignancies thereof, is devoid of
K8. De novo expression of K8 was observed for head and
neck carcinomas, however in a small patients cohort [25].
Studies including larger numbers of patients with head
and neck malignancies are to the best of our knowledge
missing so far and therefore the topic of the present inves-
tigation.
Here, we present a comprehensive survey of K8 expression
in normal mucosa, leukoplakia, head and neck squamous
cell carcinomas (HNSCC), and lymph node metastases of
the head and neck area. We have used immunohisto-
chemistry on cryosections for this purpose as it allows
thorough detection of K8 and, importantly, the assign-
ment of staining to particular cell types within samples as
opposed to RT-PCR or immunoblotting. K8 positivity was
a hallmark of transformed epithelia where it correlated
with early stages of carcinogenesis in dysplastic leukopla-
kia. K8 was also strongly over-expressed in the majority of
HNSCC tested. Importantly, K8high was a characteristic of
disseminated tumour cells and in overt lymph node
metastases. For this reason, K8 represents a valuable
marker for head and neck malignancies in early stages of
the disease and of invasive growth of tumour cells.
Methods
Tissue samples
All human samples were obtained after informed consent
according to the Helsinki Declaration and on the basis of
an approval by the local ethical committee (Ethikkommi-
sion der Medizinischen Fakultät der Ludwig-Maximilians-
Universität München; file reference N° 087/03). Fifty-
seven samples of normal mucosa were obtained from
patients suffering from chronic tonsillitis (n = 9), tonsilar
carcinomas (n = 10), laryngeal carcinomas (n = 9),
oropharyngeal carcinomas (n = 6), hypopharyngeal carci-
nomas (n = 4), carcinomas of the tongue (n = 7), mouth
(n = 4), valeculla (n = 2), vocal cords (n = 2), nasopharynx
(n = 1), alveolar ridge (n = 1), uvula (n = 1), and nasal
concha hyperplasia (n = 1). Nineteen samples of oral leu-
koplakia, six samples of lymph node metastases, and one
hundred and two samples of head and neck carcinomas of
different localisation were collected. All specimens had
been confirmed by routine clinical diagnosis according to
the UICC TNM classification of 2003 for head and neck
carcinomas [26] and histopathologic examination by two
expert pathologists. Characteristics used for the diagnosis
were tumour size (T), locoregional lymph node status
(N), and the presence of distant metastases at the time of
first diagnosis (M). Tissue specimen were shock-frozen in
liquid nitrogen and embedded in tissue-tek (Sakura, Fin-
tek, NL) to generate 4 μm non-consecutive sections.
Immunohistochemistry
The mouse anti-human K8 clone 35βH11 primary anti-
body was used (Dako, Glostrup, DK), (diluted 1:100).
Immunostaining was performed using the avidin-biotin-
peroxidase complex method (Vectastain, Vector laborato-
ries, Burlingame, CA, USA) according to the manufac-
turer's protocol. Briefly, after fixation in acetone (10 min),
endogenous peroxidase activity was inhibited upon treat-
ment with 0.03% H2O2/PBS (10 min). Before specific
staining, unspecific antigenic sites were blocked with nor-
mal goat serum or normal horse serum. Sections were
then incubated with the respective primary antibody for 1
hour at room temperature (RT) followed by incubation
with biotinylated anti-rabbit or anti-mouse immunoglob-
ulins and then with avidin-biotin-peroxidase complex (30
minutes at RT for each step). After each step, sections wereBMC Cancer 2008, 8:267 http://www.biomedcentral.com/1471-2407/8/267
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washed with PBS. Specific peroxidase activity was visual-
ized with 0.05% 3-amino-9-ethylcarbazol as a substrate
(Sigma, Deisenhofen, Germany) and 0.02% H2O2/0,1 M
Na-acetat buffer pH5.5). Counterstaining was performed
with Mayers hematoxylin. Control staining was per-
formed in the absence of primary antibody. Immunos-
tained sections were evaluated upon light microscopy by
two independent investigators. Double immunostainings
were performed with a monoclonal anti Ki67 antibody
(Dako, Glostrup, DK) using the avidin-biotin-peroxidase
method (ABC, red-brown staining), together with the K8-
specific 35βH11 antibody using alkaline phosphatase-
anti-alkaline phosphatase method and fast Blue BB salt
(Sigma, Deisenhofen, Germany) as a chromogenic sub-
strate (deep blue staining). Negative controls were con-
ducted in the absence of primary antibodies for every
detection system. Sample evaluation was performed by
two experienced researchers (BM and OG) according to
criteria of staining intensities (0-+++) published else-
where [25].
Results
K8 expression in head and neck epithelia
In a first step, we studied the expression pattern of K8 in a
small subset of tissues including normal epithelium of the
oropharynx, oral leukoplakia, and hypopharynx carcino-
mas. Appraisal of tissue integrity was performed after
hematoxilin staining, while diagnosis was conducted
beforehand by two expert pathologists according to
UICC's TNM classification. Evaluation of K8 expression
was subdivided into negative, weak, intermediate, and
strong as was described in Gires et al. [25]. K8 was not
detected in normal mucosa except for a very mild and
incidental expression in cells of the stratum basale (Figure
1A). In a hypopharynx carcinoma specimen, both micro-
scopically normal mucosa and malignant cells were adja-
cent. K8 staining allowed for a strict differentiation of
both tissues with carcinoma cells expressing high levels of
K8 while normal mucosa retained its typical staining pat-
tern restricted to some cells of the stratum basale (Figure
1B). Staining of additional leukoplakia specimens dem-
onstrated that K8 de novo expression is a fairly early event
in cell transformation, which starts in cells of the basal
membrane layer. In case regular epithelial stratification
was lost and cells of the basal membrane layer prolifer-
ated to generate multiple layers, K8 expression was strong-
est in these cells and progressed to suprabasal cells (Figure
1C). Where incipient transformation was detected, this
aberrant K8 synthesis could even be restricted to nests of
cells which proliferated, protruded in the surrounding tis-
sue, and lay in areas characterized by massive cellular
infiltrates (Figure 1D and data not shown). In hypophar-
ynx carcinomas the expression of K8 was almost in 100%
of tumour cells and mostly strong (Figure 1E), and posi-
tively correlated with the marker of proliferation Ki67
(Figure 1F).
K8 expression in diverse head and neck malignancies
Since increased or even de novo expression of K8 was char-
acteristic of transformation in a small cohort of patients
(data herein and Gires et al. 2006), we next studied K8 in
a larger collective of patients. Firstly, microscopically nor-
mal mucosas (n = 57) were assessed. Tissue specimens
originated from the oropharynx and larynx of patients suf-
fering from either chronic tonsillitis, tonsillar carcinomas,
laryngeal carcinomas, oropharyngeal carcinomas,
hypopharyngeal carcinomas, tongue carcinomas, buccal
carcinomas, carcinomas of the valeculla, vocal cords,
nasopharynx, alveolar ridge, uvula, or from nasal concha
hyperplasia. Cryosections were stained with hematoxillin
in order to appreciate tissue integrity and non-trans-
formed phenotypes. The second parameter was consid-
ered as a second appraisal following routine diagnosis by
pathologists. Except for four oropharyngeal mucosas from
tonsillar carcinoma (n = 1), oropharyngeal carcinomas (n
= 2), and carcinoma of the valeculla (n = 1), 100% of
oropharyngeal normal mucosas were devoid of K8 (Table
1). In all four divergent cases, K8 was expressed to inter-
mediate (++) or strong (+++) levels in varying percentages
of tumour cells included in the specimens. In sharp con-
trast, two laryngeal normal mucosas were strongly (+++)
positive in 100% of cells (Table 1). In summary, normal
oropharyngeal but not laryngeal mucosa was to 100%
devoid of K8.
Secondly, oral leukoplakia (n = 19), which in some cases
represented pre-malignant lesions, were stained with K8
specific antibodies. In normal or hyperplastic leukoplakia
(n = 9) 7 tissue specimens were negative for K8 (78%) and
2 specimens expressed K8 weakly in 10% and to interme-
diate levels in 5% of the cells, respectively (Table 2). Four
out of six (66.7%) dysplastic leukoplakia expressed K8 to
intermediate (++) or even strong (+++) levels in varying
percentages of cells. Four leukoplakia samples actually
represented carcinomas of small sizes (T1-2) and all
expressed K8 to strong (+++) levels (Table 2).
Six lymph node metastases (LNM) from primary carcino-
mas of different origin expressed K8 to intermediate or
strong levels and with a percentage range of positive cells
from 5–100% (Table 3). Interestingly, three out of six
LNM displayed a strong (+++) K8 expression in 100% of
cells.
In a last step, we assessed the expression of K8 in carcino-
mas (n = 102) of various localizations including
hypopharynx (n = 10), oro-hypopharynx (n = 2), larynx
(n = 23), oropharynx (n = 13), larynx-hypopharynx (n =
2), vocal cords (n = 2), mouth (n = 6), tonsil (n = 15),BMC Cancer 2008, 8:267 http://www.biomedcentral.com/1471-2407/8/267
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K8 expression pattern in head and neck epithelia Figure 1
K8 expression pattern in head and neck epithelia. K8 was visualised by immunohistochemistry with specific antibodies 
in normal mucosa (A), hypopharynx carcinoma with adjacent normal mucosa (B), oral leukoplakia (C, D), hypopharynx carci-
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Table 1: K8 expression in normal mucosa.
PATIENT K8 INTENSITY % OF TISSUE LOCALISATION OF MUCOSA
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Tonsillitis - / oropharynx
chron. Laryngitis - / oropharynx
chron. Tonsillitis - / oropharynx
Ton Ca +++ 80 oropharynx *
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Ton Ca - / oropharynx
Larynx Ca - / oropharynx
Larynx neoplasia - / oropharynx
Larynx Ca - / oropharynx
Larynx Ca - / oropharynx
Larynx Ca - / oropharynx
Larynx Ca - / oropharynx
Larynx Ca - / oropharynx
Larynx Ca +++ 100 larynx
Larynx Ca +++ 100 larynx
Oropharynx Ca - / oropharynx
Oro-Hypopharynx Ca +++ 20 oropharynx *
Oropharynx Ca - / oropharynx
Oropharynx Ca - / oropharynx
Oropharynx Ca - / oropharynx
Oropharynx Ca +++ 40 oropharynx *
Hypopharynx Ca - / oropharynx
Hypopharynx Ca - / oropharynx
Hypopharynx Ca - / oropharynx
Larynx-Hypopharynx Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Tongue Ca - / oropharynx
Mouth Ca - / oropharynx
Mouth Ca - / oropharynx
Mouth Ca - / oropharynx
Mouth Ca - / oropharynx
Vallecula Ca ++ 20 oropharynx *
Vallecula Ca - / oropharynx
Vocal cords Ca - / oropharynx
Vocal cords Ca - / oropharynx
Nasopharynx Ca - / oropharynx
Alveolar ridge Ca - / oropharynx
Uvula Ca - / oropharynx
Nasal concha hyperplasia - / nasal epithelium
Given are the intensity of K8 expression, diagnostic findings, percentages of positive cells within affected tissues, and localisation of the healthy 
mucosa.
-: no staining; +: weak; ++: intermediate, +++: strong. Chron. Tonsillitis: chronic tonsillitis; Ton Ca: tonsillar carcinoma.
*: CK8-positive cells represented either dysplatic or carcinoma cells within samples assessed.BMC Cancer 2008, 8:267 http://www.biomedcentral.com/1471-2407/8/267
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valecula (n = 13), and tongue (n = 16). Evaluation of K8
intensities in these malignancies demonstrated that inter-
mediate and especially strong K8 expression was charac-
teristic of head and neck carcinomas, independently of
the sub-localization (Figure 2A). Negative or weak K8
expression accounted only for maximally 37.5% as seen
for tongue carcinomas and was generally below 20%
(mean value 11.65% ± 12). Oppositely, intermediate and
strong K8 staining was seen in 62.5% to 100% of all cases
(Figure 2B; mean value 88.25% ± 11.5).
K8 expression in disseminated and tumour cells and 
metastases
Staining of various carcinoma samples with hematoxillin/
eosin revealed the presence of tumour cells that had
detached from the primary tumour into surrounding tis-
sue at the time point of surgery. These disseminated
tumour cells (DTCs) were in the close proximity of the
bulk of carcinoma cells and were present either as single
cells or as small nests composed of up to 15–30 cells.
Immunohistochemical staining of these samples with
antibodies specific for K8 strongly marked detached cells.
Interestingly, K8 expression in DTCs was often superior to
cells of the primary tumour suggesting a need for single
cells to overexpress K8 (Figure 3). Noteworthy, detached
and K8 positive cells were commonly not seen within
densely packed infiltrates of immune cells but rather in
loosened areas of the tissue specimens. In accordance with
those findings, K8 positive cells with the highest expres-
sion levels often came to localize at the edge of tissue pro-
truding into the submucosa, eventually generating a
remarkable lining of K8high  cells, i.e. cells displaying
strong K8 expression (Figure 4A). Since K8high was a hall-
mark of detached carcinoma cells, we next analyzed its
pattern in lymph node metastases of tonsillar carcinomas.
Again K8high was strictly confined to islets of metastatic
tumour cells (Figure 4B).
Discussion
Reliable markers for pre-malignant lesions retained their
paramount importance, as they are believed to bring
about significant improvements of patients' care and over-
all survival [27]. This notion was best exemplified by the
use of prostate-specific antigen PSA for the early diagnosis
of prostate carcinoma [28]. Clearly, the earlier a malig-
nancy of the head and neck area is diagnosed, the better
the prognosis for the patient [29]. Hence, detection of pre-
malignant lesions is highly desirable as is the visualiza-
tion of disseminated tumour cells, which are to be seen as
founders of metastases [30-32]. With these prerequisites
in mind it is interesting to retrieve from the present stuy
that K8 (i) is absent in normal mucosa composed of squa-
mous epithelium and in contrast to adenomatous epithe-
lium, that (ii) K8 expression differentiates dysplastic
lesions, carcinomas in situ, and small established carcino-
mas (i.e.  T1-2) from normal tissue and hyperplastic
lesions within oral leukoplakia, and finally that (iii) K8
thoroughly marks single detached tumour cells. These fea-
tures and the de novo expression of qualify K8 as a worth
candidate for the early detection of pre-malignant lesions,
which might progress to overt malignancies with signifi-
cantly enhanced probability [33], and for disseminated
Table 2: K8 expression in oral leukoplakia.
LP K8 INTENSITY % OF TISSUE DIAGNOSTIC FINDINGS
1 -/ n o r m a l
9 -/ n o r m a l
11 -/ n o r m a l
5 - / hyperplasia
6 - / hyperplasia
7 - / hyperplasia
4 - / hyperplasia
14 + 10 hyperplasia
19 ++ 5 hyperplasia
2 - / dysplasia (weak)
12 - / dysplasia
8 ++ 10 dysplasia
10 +++ 90 dysplasia
13 ++ 5 dysplasia
18 +++ 10 dysplasia
17 +++ 10 SCC, G1
15 +++ 20 T2, N0, Mx, G3
16 +++ 20 T1, Nx, Mx, G1
3 +++ 100 T1, G2-3
Given are the intensity of K8 expression, diagnostic findings accoding to TNM classification, and percentages of positive cells within affected tissues.
-: no staining; +: weak; ++: intermediate, +++: strong.
SCC: squamous cell carcinoma, no TNM status available; LP: leukoplakia.BMC Cancer 2008, 8:267 http://www.biomedcentral.com/1471-2407/8/267
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tumour cells in head and neck carcinomas. Additionally,
K8 was released as a circulating marker from apoptotic
non-small cell lung carcinoma cells as a full-length and
proteolytic cleavage-resistant protein and might hence
represent a valuable biomarker for head and neck malig-
nancies [34].
From a mechanistic and molecular point of view, and
with respect to the over-expression of K8 in cancer cells,
two eventualities are to be envisaged. Firstly, disseminat-
ing and invading cells might require a reorganization of
their cytoskeleton to improve motility and epithelial-to-
mesenchymal transition (EMT), which could be war-
ranted by keratins of simple epithelia as is K8. Data from
Chu and colleagues disclosed an ability of K8 and K18 to
foster the invasive potential when ectopically expressed in
murine L fibroblasts [16]. Along this line, assessment of
p38 kinase activity in disseminated cells appears expedi-
ent. K8 Ser73 serves as a substrate for p38 kinase and phos-
phorylation at this position is crucial for the
destabilization of intermediate filaments [3,5,35]. Reor-
ganization, especially destabilization of intermediate fila-
ments occurs under various physiological conditions such
as mechanic stress, during epithelial cell homeostasis,
exposure to chemicals (vanadate, ocadaic acid), and dur-
ing mitosis. Common to all these processes is the recruit-
ment of active p38 kinase to depolimerized keratin
granules and phosphorylation of K8 at Ser73  [5,11].
Hence, one may also envisage the simultaneous assesse-
ment of K8 expression and of Ser73 phosphorylation as an
additional surrogate marker for the mitotic index. A sec-
ond scenario must be considered, in which K8 serves as a
receptor for plasminogen and tPA at the plasma mem-
brane of tumour cells [12-14]. By doing so, K8 will
enhance the proteolytic activity at the plasma membrane
and facilitate tissue remodelling and invasion. Such an
eventuality is supported by data presented herein. Single
tumour cells that were already detached from the main
tumour at the time of sample asservation displayed high-
est K8 expression, which may foster proteolytic activity
and invasion. Regulatory processes involved in the de
novo expression of K8 in these tumour cells are poorly
understood. Recent work by Lacina et al. disclosed a
potential for non-malignant stroma cells, i.e.  tumour-
associated fibroblasts, to induce K8 expression on normal
keratinocytes in vitro [36,37]. Thus, the tumour microen-
vironment needs to be seen as a strong modulator of pro-
tein cell surface expression of carcinoma cells. Clearly,
both eventualities, namely remodelling of cell structures
and improvement of the proteolytic appartus of carci-
noma cells, are not mutually exclusive but may even be
both instrumental in parallel.
The findings presented in this study of K8 expression are
in accordance with and complementing previous data that
demonstrated de novo synthesis of K8 in dysplastic lesions
as well as in head neck carcinomas. However, these former
studies were conducted in substantially smaller cohorts
and without differentiation of tumour sub-localizations
[25,38]. Subdividing head and neck tissues according to
their precise localization revealed minor differences in the
K8 expression profile. Hypopharynx, oropharynx, larynx,
Table 3: K8 expression in lymph node metastases.
LNM K8 INTENSITY % OF TISSUE TNM/G
CUP ++ 5 G2
Soft palate Ca ++ 5 T2/G2
CUP ++ 70 G3
Adenocystic Ca +++ 100 G3
Tonsillar Ca +++ 100 T2/G2
Tongue Ca +++ 100 T2/G2
Given are the intensity of K8 expression, diagnostic findings of the 
cognate carcinoma accoding to TNM classification and grading (G), 
and percentages of positive cells within affected tissues.
-: no staining; +: weak; ++: intermediate, +++: strong.
Ca: carcinoma, CUP: carcinoma of unknown primary.
K8 expression in head and neck squamous cell carcinomas Figure 2
K8 expression in head and neck squamous cell carci-
nomas. (A) K8 was visualised by immunohistochemistry 
with specific antibodies in the indicated specimens of 
HNSCC, expression intensities are given as "no staining" (-), 
"weak staining" (+), "intermediate staining" (++), and "strong 
staining" (+++). (B) K8 staining intensities of tumour speci-
mens are depicted as percentages of all specimens from one 
given origin.BMC Cancer 2008, 8:267 http://www.biomedcentral.com/1471-2407/8/267
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valecula, and vocal cords were characterized by > 85% of
samples expressing intermediate to strong levels of K8. In
contrast, carcinomas of the tongue were different since
they displayed a more heterogeneous repartition with
37.5% of samples expressing no or weak levels of K8.
Also, normal mucosa from the larynx was always positive
for K8, pinpointing differences amongst healthy epithelia,
too. Therefore, tongue and laryngeal carcinomas appear
less amenable to a K8-based diagnosis.
Taken together our data qualify K8 as an excellent marker
for head and neck carcinomas, lymph node metastases,
and for tumour cells that have already detached from the
primary tumour.
Conclusion
The intermediate filament protein K8 is known as a
tumour-associated antigen. We present a survey of K8
expression in head and neck epithelia that demonstrates
the specific staining of K8 in pre-malignant and malignant
tissue versus normal cells. Dysplastic and tumour cells
expressed K8 to strong levels, as did disseminated tumour
cells. Hence, K8 is an excellent marker for the visualisation
and diagnosis of pre-malignancies and DTCs in the head
and neck area.
Abbreviations
K8: cytokeratin 8; K18: cytokeratin 18; DTC: disseminated
tumour cell; HNSCC: head and neck squamous cell carci-
K8 expression in detached tumour cells Figure 3
K8 expression in detached tumour cells. K8 was visualised by immunohistochemistry with specific antibodies in head and 
neck carcinoma specimens. Depicted are tumours cells that had detached from the primary tumour at the time of surgery and 
occurred as single cells or small islets of tumour cells (less than 30 cells).
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